Sanofi and Translate Bio Initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate
12 Mar 2021
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.
EUREKA THERAPEUTICS ANNOUNCES SUCCESSFUL PRECLINICAL RESULTS OF INVISIMASKTM HUMAN ANTIBODY NASAL SPRAY AGAINST SARS-COV-2 INFECTION
14 Dec 2020
Eureka used a human antibody as the spike protein binder to reduce the risk of adverse effects from immunogenicity which might occur if the binder was an antibody of animal origin or a foreign peptide.
Merck to Acquire OncoImmune
23 Nov 2020
"Meaningful new therapeutic options are desperately needed for possibly millions of people around the world who will develop severe or critical COVID-19 disease," said Dr. Roger M. Perlmutter, President Merck Research Laboratories.
ImmunityBio Gets FDA Authorisation to Begin Trial of Novel Covid-19 Vaccine Candidate
31 Oct 2020
Sanofi and GSK to Support COVAX with 200 Million Doses of Adjuvanted, Recombinant Protein-based COVID-19 Vaccine
28 Oct 2020
Novartis Announces Collaboration with Molecular Partners to Develop Two DARPin® Therapies Designed for Potential Use Against COVID-19
28 Oct 2020
Basel, October 28, 2020 — Novartis and Molecular Partners AG today announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners' anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423.
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
23 Sep 2020
Integral Molecular Awarded Grant from the Commonwealth of Pennsylvania to Advance COVID-19 Research
18 Sep 2020
Join Our Newsletter for Free
